Radient Pharmaceuticals Corporation fka RXPC

[GetSeriousOK]

GCDx should just call it "LC Sentinel."

Provista wouldn't mind. Radient, of course, has no say in the matter.

Here's what GCDx says about their LC test on Fundable:

https://www.fundable.com/the-lung-cancer-test

"Utilizing these proprietary cancer biomarkers, coupled with a mathematical algorithm, The Lung Cancer Test can detect the presence of lung cancer in high-risk populations with a sensitivity of 87% and a specificity of 95%. The overall accuracy of the test is 97%, defined by the area under the receiver-operating characteristic (ROC) curve."

Here's what Provista said about LC Sentinel in 2010:

"The data generated in this final study proved consistent with previous findings and produced positive clinical performance marks of 87% sensitivity; 95% specificity; and an ROC Accuracy of 0.97. "

http://www.marketwired.com/press-release/radient-pharmaceuticals-provista-life-sciences-announce-new-blood-test-lung-cancer-nyse-amex-rpc-1334094.htm

Could this be any more obvious?